Samhällsförvärvad C difficile-associerad diarré en realitet: Färbe recept och mera tvål

Lakartidningen

Volumn , Issue 23, 1997, Pages 2187-2192

  Karlström, Olle ^a,d   Fryklund, Birgitta ^a,b   Tullus, Kjell ^c   Burman, Lars G ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b Och Vårdhögskolan   (Sweden)

^c Barnkliniken   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; DRUG UTILIZATION; HUMAN; HYGIENE; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; SWEDEN;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; HUMANS; HYGIENE; INCIDENCE; SWEDEN;

EID: 0031552453     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459-77.
2. Svenungsson B. Clostridium difficile-associerad diarré - ett ökande problem. Läkartidningen 1996; 93: 2931-4.
3. Macgowan AP, Brown I, Feeney R, Lovering A, McCulloch SY, Reeves DS et al. Clostridium difficile-associated diarrhoea and length of hospital stay (brev). J Hosp Infect 1995; 31: 241-4.
4. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162: 678-84.
5. Nelson DE, Auerbach SB, Baltch AL, Desjardin E, Beck-Sague C, Rheal C et al. Epidemic Clostridium difficile-associated diarrhea: role of second- and third generation cephalosporins. Infect Control Hosp Epidemiol 1994; 15: 88-94.
6. Chachaty E, Depitre C, Mario N, Bourneix C, Saulnier P, Corthier G et al. Presence of Clostridium difficile and antibiotic and B-laktamase activities in feces of volunteers treated with oral Cefixime, oral Cefpodoxime Proxetil, or placebo. Antimicrob Agents Chemother 1992; 36: 2009-13.
7. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
8. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and reinfections. J Hospital Infect 1992; 22: 85-92.
9. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-8.
10. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-10.
11. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996; 100: 32-40.
12. Cerquetti M, Ida L, Caprioli A, Sebastianelli A, Mastrantonio P. Role of Clostridium difficile in childhood diarrhea. Pediatr Infect Dis J 1996; 14: 598-603.
13. Tullus K, Aronsson B, Marcus S, Möllby R. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Microbiol Infect Dis 1989; 8: 390-3.
14. Struelens MJ, Maas A, Nonhoff C, Deplano A, Rost F, Serruys E et al. Control of nosocomial transmission of Clostridium difficile based on sporadic case surveillance. Am J Med 1991; 91 suppl 3B: 138-44.